SEC Form 4 · accession 0001677036-26-000004
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Robert Lind
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.96 | Jun 2, 2026 | A | 20,100 | A | — | Jun 2, 2036 | Common Stock | 20,100 | 20,100 | D |
Explanation of responses
- F1The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.